1. The paper mentions an Mpox outbreak declared a PHEIC by the WHO on August 14, 2024. But the current date is only 2025. Is this a typo? Did they mean 2022 or 2023?
2. The introduction talks about an “interdisciplinary approach” including Visual Arts and Social Sciences, but the rest of the provided text seems very focused on virology, diagnostics, and nanotechnology. How are the Visual Arts and Social Sciences specifically integrated into the research on Mpox prevention?
3. The text mentions different sub-branches of the virus (like B.1, C.1.1) but doesn’t explain what these genetic variations mean for the virus’s behavior, transmission, or severity. What is the significance of these different sub-branches?
4. It says the EEV form of the virus has 25 membrane proteins. Are any of these proteins (like A35R, A36R, B6R) being targeted by the new nanobiosensors or nanovaccines mentioned in the paper’s title?
5. The paper references industries like Joysbio and VivaChek developing rapid antigen tests. Are these tests already available? How do their sensitivity and specificity compare to PCR tests?
6. The authors are experts in nanobiosensors. What specific type of nanobiosensor (e.g., electrochemical, optical) do they propose as the most promising for Mpox detection, and why?